Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB) and Cencora (COR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvation Bio (NUVB – Research Report) and Cencora (COR – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuvation Bio (NUVB)
In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Nuvation Bio, with a price target of $11.00. The company’s shares closed last Tuesday at $4.40.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
Currently, the analyst consensus on Nuvation Bio is a Strong Buy with an average price target of $12.00, representing a 165.5% upside. In a report issued on March 3, JonesTrading also maintained a Buy rating on the stock with a price target.
See the top stocks recommended by analysts >>
Cencora (COR)
Argus Research analyst David Toung reiterated a Buy rating on Cencora yesterday and set a price target of $400.00. The company’s shares closed last Tuesday at $334.71.
According to TipRanks.com, Toung is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cencora with a $411.44 average price target, a 21.0% upside from current levels. In a report issued on March 7, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $402.00 price target.
